Sparsentan in IgA Nephropathy : The PROTECT trial — NephJC
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
Few older adults with kidney failure engage in shared decision-making (SDM) for kidney replacement therapy. Absence of instruments assessing SDM-relevant knowledge domains may contribute to…
“Updates on Public Policy for Nephrology 2024: From the Hill and Medicare to Nephrology Practice” published on 08 Apr 2024 by American Society of Nephrology.
SAN DIEGO — Transplant physicians should have a patient care plan in place when helping patients deal with the distress and anxiety after a failed…
This literature review combined with clinical experience provides dosing recommendations for patients undergoing intermittent hemodialysis. The information presented could be beneficial for clinicians caring for…
Please complete this form to join ASN in celebrating Asian American and Pacific Islander Heritage Month. Share your own experiences or nominate someone in the…
One platform for education, engagement & exchange: courses, conferences, call for abstracts, publishing & more…
In 1988, the American Board of Internal Medicine (ABIM) defined essential procedural skills in nephrology, and candidates for ABIM certification were required to present evidence…
Objectives To estimate the effects of nationwide replacement of discretionary salt (used at table or during cooking) with potassium enriched salt substitute on morbidity and…
This week, we will discuss the SSASS trial. in which a simple switch of table salt with a K-enriched salt works miracles. Is it about…